Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.


Press Releases

14 October 2020

Pfizer and BioNTech Announce New England Journal of Medicine Publication of Pha..

14 October 2020

BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs ..

9 October 2020

Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SAR..

Press releases (more)

Upcoming Events

November 10, 2020

Third Quarter 2020 update

Upcoming events (more)

Stock Quote

Oct 29, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.